Page last updated: 2024-10-22

amlodipine and Obesity

amlodipine has been researched along with Obesity in 42 studies

Amlodipine: A long-acting dihydropyridine calcium channel blocker. It is effective in the treatment of ANGINA PECTORIS and HYPERTENSION.
amlodipine : A fully substituted dialkyl 1,4-dihydropyridine-3,5-dicarboxylate derivative, which is used for the treatment of hypertension, chronic stable angina and confirmed or suspected vasospastic angina.

Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).

Research Excerpts

ExcerptRelevanceReference
"Aliskiren penetrates adipose and skeletal muscle in hypertensive patients with abdominal obesity and reduces renin-angiotensin-aldosterone system activity."9.24Systemic and tissue-specific effects of aliskiren on the RAAS and carbohydrate/lipid metabolism in obese patients with hypertension. ( Boschmann, M; Dahlke, M; Danser, AHJ; Dole, WP; Engeli, S; Jordan, J; May, M; Nussberger, J; Pal, P; Prescott, MF; Stitah, S, 2017)
"This prespecified subgroup analysis of a phase III study examined the effect of adding hydrochlorothiazide (HCTZ) to olmesartan (OLM)/amlodipine (AML) in patients with moderate to severe hypertension stratified by age, sex, body mass index, and hypertension severity."9.19Efficacy and tolerability of triple-combination therapy with olmesartan, amlodipine, and hydrochlorothiazide: a subgroup analysis of patients stratified by hypertension severity, age, sex, and obesity. ( Ammentorp, B; de la Sierra, A; Kreutz, R; Laeis, P, 2014)
"After a 4-week placebo period, 58 overweight-obese (BMI >or=25 kg/m(2)) patients, with mild to moderate essential hypertension (DBP >95 and <110 mmHg, SBP >140 mmHg) were treated with amlodipine 5 mg od or valsartan 160 mg od or amlodipine 5 mg plus valsartan 160 mg od for 8 weeks according to a randomized, open-label, blinded end-point, cross-over study."9.13Effect of valsartan addition to amlodipine on insulin sensitivity in overweight-obese hypertensive patients. ( Corradi, L; Derosa, G; Fogari, R; Lazzari, P; Mugellini, A; Preti, P; Santoro, T; Zoppi, A, 2008)
"The objective of this study was to assess the effect of amlodipine-atorvastatin combination on plasma interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha) and insulin sensitivity in normocholesterolemic obese hypertensive patients."9.12Effects of amlodipine-atorvastatin combination on inflammation markers and insulin sensitivity in normocholesterolemic obese hypertensive patients. ( Ciccarelli, L; Corradi, L; Derosa, G; Fogari, E; Fogari, R; Lazzari, P; Preti, P; Zoppi, A, 2006)
"To demonstrate that calcium channel blockers can improve insulin resistance clinically, we investigated the effects of the calcium channel blockers, amlodipine, manidipine and cilnidipine on serum levels of steroid hormones and insulin."9.11Effects of the long-acting calcium channel blockers, amlodipine, manidipine and cilnidipine on steroid hormones and insulin resistance in hypertensive obese patients. ( Miyachi, Y; Ueshiba, H, 2004)
"We investigated the effects of the calcium channel blocker amlodipine besilate on serum levels of adrenal androgens and insulin in 20 men with essential hypertension and obesity (age: 51."7.71Effects of amlodipine on serum levels of adrenal androgens and insulin in hypertensive men with obesity. ( Miyachi, Y; Tsuboi, K; Ueshiba, H, 2001)
"To evaluate the effects of long-term treatment antihypertensive with the dihydropyridine calcium antagonist amlodipine on insulin sensitivity, plasma insulin, and lipoprotein metabolism in obese hypertensive patients."7.68Lack of effect of long-term amlodipine on insulin sensitivity and plasma insulin in obese patients with essential hypertension. ( Böhlen, L; de Courten, M; Ferrari, P; Heynen, G; Riesen, W; Schneider, M; Shaw, S; Weidmann, P, 1993)
"Hypertension is particularly prevalent in patients aged ≥65 years, those with a body mass index ≥30 kg m(-2), Blacks and those with type II diabetes."6.75Efficacy and tolerability of amlodipine plus olmesartan medoxomil in patients with difficult-to-treat hypertension. ( Chrysant, SG; Heyrman, R; Karki, S; Lee, J; Melino, M, 2010)
"Aliskiren is a novel renin-angiotensin aldosterone system (RAAS) inhibitor, the combination therapy of aliskiren and amlodipine for blood pressure control have been reported recently."6.49Aliskiren and amlodipine in the management of essential hypertension: meta-analysis of randomized controlled trials. ( Chen, K; Han, Y; Kou, X; Liu, Y; Zeng, C; Zhou, L, 2013)
"Candesartan treatment may suppress all-cause death and reduce the incidence of new-onset diabetes in patients with obesity."5.36Role of diabetes and obesity in outcomes of the candesartan antihypertensive survival evaluation in Japan (CASE-J) trial. ( Fujimoto, A; Hirata, M; Nakao, K; Oba, K; Ogihara, T; Saruta, T; Ueshima, K; Yasuno, S, 2010)
"Aliskiren penetrates adipose and skeletal muscle in hypertensive patients with abdominal obesity and reduces renin-angiotensin-aldosterone system activity."5.24Systemic and tissue-specific effects of aliskiren on the RAAS and carbohydrate/lipid metabolism in obese patients with hypertension. ( Boschmann, M; Dahlke, M; Danser, AHJ; Dole, WP; Engeli, S; Jordan, J; May, M; Nussberger, J; Pal, P; Prescott, MF; Stitah, S, 2017)
" We prospectively examined randomization to first-step chlorthalidone, a thiazide-type diuretic; amlodipine, a calcium-channel blocker; and lisinopril, an angiotensin-converting enzyme inhibitor, on BP control and cardiovascular outcomes in a hypertensive cohort stratified by baseline BMI [kg/m(2); normal weight (BMI <25), overweight (BMI = 25-29."5.19Blood pressure control and cardiovascular outcomes in normal-weight, overweight, and obese hypertensive patients treated with three different antihypertensives in ALLHAT. ( Barzilay, JI; Dart, RA; Davis, BR; Einhorn, PT; Graves, JW; Pressel, SL; Reisin, E; Retta, TM; Saklayen, MG; Yamal, JM, 2014)
"This prespecified subgroup analysis of a phase III study examined the effect of adding hydrochlorothiazide (HCTZ) to olmesartan (OLM)/amlodipine (AML) in patients with moderate to severe hypertension stratified by age, sex, body mass index, and hypertension severity."5.19Efficacy and tolerability of triple-combination therapy with olmesartan, amlodipine, and hydrochlorothiazide: a subgroup analysis of patients stratified by hypertension severity, age, sex, and obesity. ( Ammentorp, B; de la Sierra, A; Kreutz, R; Laeis, P, 2014)
"This was a prospective trial of amlodipine 10 mg/day administered for 1 month in primary-care patients with hypertension (n = 28), 46% of whom were obese and 57% of whom displayed the metabolic syndrome."5.15Blood pressure-lowering response to amlodipine as a determinant of the antioxidative activity of small, dense HDL3. ( Bittar, R; Bonnefont-Rousselot, D; Bruckert, E; Chantepie, S; Chapman, MJ; Girerd, X; Hansel, B; Kontush, A; Orsoni, A, 2011)
"After a 4-week placebo period, 58 overweight-obese (BMI >or=25 kg/m(2)) patients, with mild to moderate essential hypertension (DBP >95 and <110 mmHg, SBP >140 mmHg) were treated with amlodipine 5 mg od or valsartan 160 mg od or amlodipine 5 mg plus valsartan 160 mg od for 8 weeks according to a randomized, open-label, blinded end-point, cross-over study."5.13Effect of valsartan addition to amlodipine on insulin sensitivity in overweight-obese hypertensive patients. ( Corradi, L; Derosa, G; Fogari, R; Lazzari, P; Mugellini, A; Preti, P; Santoro, T; Zoppi, A, 2008)
"The objective of this study was to assess the effect of amlodipine-atorvastatin combination on plasma interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha) and insulin sensitivity in normocholesterolemic obese hypertensive patients."5.12Effects of amlodipine-atorvastatin combination on inflammation markers and insulin sensitivity in normocholesterolemic obese hypertensive patients. ( Ciccarelli, L; Corradi, L; Derosa, G; Fogari, E; Fogari, R; Lazzari, P; Preti, P; Zoppi, A, 2006)
"To demonstrate that calcium channel blockers can improve insulin resistance clinically, we investigated the effects of the calcium channel blockers, amlodipine, manidipine and cilnidipine on serum levels of steroid hormones and insulin."5.11Effects of the long-acting calcium channel blockers, amlodipine, manidipine and cilnidipine on steroid hormones and insulin resistance in hypertensive obese patients. ( Miyachi, Y; Ueshiba, H, 2004)
"The primary objective of this study was to determine whether combination therapy with valsartan 160 mg plus hydrochlorothiazide (HCTZ) 25 mg OD would be more effective than monotherapy with amlodipine 10 mg OD in reducing systolic blood pressure (SBP) in patients with moderate (stage II) hypertension and > or =1 other cardiovascular risk factor or concomitant condition."5.11Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study. ( Bönner, G; Heintz, D; Kandra, A; Khder, Y; Malacco, E; Ruilope, LM, 2005)
" This article considers the evidence supporting telmisartan/amlodipine combination therapy for the treatment of hypertension in patients with metabolic risk factors."4.89Telmisartan plus amlodipine single-pill combination for the management of hypertensive patients with a metabolic risk profile (added-risk patients). ( Ley, L; Schumacher, H, 2013)
"The CD feeding induced obesity, hyperphagia, hyperlipidaemia, and leptin and insulin resistance."3.80Chronic blockade of angiotensin AT₁ receptors improves cardinal symptoms of metabolic syndrome in diet-induced obesity in rats. ( Barkhausen, J; Hübel, N; Mildner, M; Müller-Fielitz, H; Raasch, W; Vogt, FM, 2014)
" Metformin treatment improved the insulin sensitivity, and normalized the in vitro bladder hypercontractility and cystometric dysfunction in obese mice."3.78Role of PKC and CaV1.2 in detrusor overactivity in a model of obesity associated with insulin resistance in mice. ( Anhê, GF; Antunes, E; Calixto, MC; De Nucci, G; Grant, AD; Leiria, LO; Lintomen, L; Mónica, FZ; Sollon, C; Zanesco, A, 2012)
"We investigated the effects of the calcium channel blocker amlodipine besilate on serum levels of adrenal androgens and insulin in 20 men with essential hypertension and obesity (age: 51."3.71Effects of amlodipine on serum levels of adrenal androgens and insulin in hypertensive men with obesity. ( Miyachi, Y; Tsuboi, K; Ueshiba, H, 2001)
" Each of five groups of obese hypertensives were treated with the long-acting calcium channel blocker (CCB) amlodipine, the angiotensin converting enzyme (ACE) inhibitor enalapril with or without a weight reduction program, or a weight reduction program alone."3.71Weight reduction and pharmacologic treatment in obese hypertensives. ( Masuo, K; Mikami, H; Ogihara, T; Tuck, ML, 2001)
"To evaluate the effects of long-term treatment antihypertensive with the dihydropyridine calcium antagonist amlodipine on insulin sensitivity, plasma insulin, and lipoprotein metabolism in obese hypertensive patients."3.68Lack of effect of long-term amlodipine on insulin sensitivity and plasma insulin in obese patients with essential hypertension. ( Böhlen, L; de Courten, M; Ferrari, P; Heynen, G; Riesen, W; Schneider, M; Shaw, S; Weidmann, P, 1993)
"Hypertension and obesity are two major threats for public health."2.80The Effects of Valsartan and Amlodipine on the Levels of Irisin, Adropin, and Perilipin. ( Akkaya, N; Cakmak, M; Çelik, HT; Demircelik, B; Erdamar, H; Gok, S; Kazanci, F; Yigitoglu, R, 2015)
"Hypertension is particularly prevalent in patients aged ≥65 years, those with a body mass index ≥30 kg m(-2), Blacks and those with type II diabetes."2.75Efficacy and tolerability of amlodipine plus olmesartan medoxomil in patients with difficult-to-treat hypertension. ( Chrysant, SG; Heyrman, R; Karki, S; Lee, J; Melino, M, 2010)
"Amlodipine was used as the control drug."2.72Selective imidazoline agonist moxonidine in obese hypertensive patients. ( de Abreu, VG; Francischetti, EA; Sanjuliani, AF, 2006)
"Amlodipine treatment 1) lowered fasting serum insulin (from 273 +/- 19 to 200 +/- 17 pmol/L; P < 0."2.67The calcium channel blocker amlodipine raises serum dehydroepiandrosterone sulfate and androstenedione, but lowers serum cortisol, in insulin-resistant obese and hypertensive men. ( Beer, NA; Beer, RM; Jakubowicz, DJ; Nestler, JE, 1993)
"Aliskiren is a novel renin-angiotensin aldosterone system (RAAS) inhibitor, the combination therapy of aliskiren and amlodipine for blood pressure control have been reported recently."2.49Aliskiren and amlodipine in the management of essential hypertension: meta-analysis of randomized controlled trials. ( Chen, K; Han, Y; Kou, X; Liu, Y; Zeng, C; Zhou, L, 2013)
"Treatment with amlodipine, candesartan, or indapamide did not significantly affect plasma visfatin levels."1.43Effects of antihypertensive treatment on plasma apelin, resistin, and visfatin concentrations. ( Piecha, G; Skoczylas, A; Więcek, A, 2016)
"Candesartan treatment may suppress all-cause death and reduce the incidence of new-onset diabetes in patients with obesity."1.36Role of diabetes and obesity in outcomes of the candesartan antihypertensive survival evaluation in Japan (CASE-J) trial. ( Fujimoto, A; Hirata, M; Nakao, K; Oba, K; Ogihara, T; Saruta, T; Ueshima, K; Yasuno, S, 2010)
"Non-alcoholic steatohepatitis (NASH), which is a common liver disease in industrialized countries, is associated with obesity, hypertension, and type-2 diabetes (metabolic syndrome)."1.35ACE inhibition and AT1 receptor blockade prevent fatty liver and fibrosis in obese Zucker rats. ( Cao, G; Mastai, R; Mella, J; Muñoz, MC; Pereyra, L; Toblli, JE, 2008)
"Heart failure was two times more prevalent in obese patients."1.34[Overweight and obesity in hypertensive Spanish patients. The CORONARIA study]. ( Aguilar Llopis, A; Arístegui Urrestarazu, R; Armada Peláez, B; Cosín Aguilar, J; Hernándiz Martínez, A; Masramón Morell, X; Rodríguez Padial, L; Zamorano Gómez, JL, 2007)

Research

Studies (42)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's3 (7.14)18.2507
2000's15 (35.71)29.6817
2010's23 (54.76)24.3611
2020's1 (2.38)2.80

Authors

AuthorsStudies
Chou, CL1
Li, CH1
Fang, TC1
Engeli, S4
May, M2
Nussberger, J2
Danser, AHJ1
Dole, WP1
Prescott, MF2
Dahlke, M2
Stitah, S1
Pal, P1
Boschmann, M2
Jordan, J4
Stinkens, R1
van der Kolk, BW1
Jax, T1
Heise, T1
Jocken, JW1
Schindler, C1
Havekes, B1
Schaper, N1
Albrecht, D1
Kaiser, S1
Hartmann, N1
Letzkus, M1
Langenickel, TH1
Goossens, GH1
Blaak, EE1
Roth, EM1
Oparil, S1
Melino, M2
Lee, J2
Fernandez, V1
Heyrman, R2
Liu, Y1
Chen, K1
Kou, X1
Han, Y1
Zhou, L1
Zeng, C1
Sweiss, N1
Sharma, K1
Müller-Fielitz, H1
Hübel, N1
Mildner, M1
Vogt, FM1
Barkhausen, J1
Raasch, W1
Reisin, E1
Graves, JW1
Yamal, JM1
Barzilay, JI1
Pressel, SL1
Einhorn, PT1
Dart, RA1
Retta, TM1
Saklayen, MG1
Davis, BR1
Kreutz, R1
Ammentorp, B1
Laeis, P1
de la Sierra, A1
Olszanecka-Glinianowicz, M1
Smertka, M1
Almgren-Rachtan, A1
Chudek, J1
Çelik, HT1
Akkaya, N1
Erdamar, H1
Gok, S1
Kazanci, F1
Demircelik, B1
Cakmak, M1
Yigitoglu, R1
Skoczylas, A1
Piecha, G1
Więcek, A1
Fogari, R2
Preti, P2
Zoppi, A2
Mugellini, A1
Corradi, L2
Lazzari, P2
Santoro, T1
Derosa, G2
Chrysant, SG1
Karki, S1
Nakao, K1
Hirata, M1
Oba, K1
Yasuno, S1
Ueshima, K1
Fujimoto, A1
Ogihara, T2
Saruta, T1
Sowers, JR2
Raij, L2
Jialal, I1
Egan, BM2
Ofili, EO1
Samuel, R2
Zappe, DH2
Purkayastha, D2
Deedwania, PC1
Punzi, H1
Shojaee, A2
Waverczak, WF1
Maa, JF2
Hansel, B1
Girerd, X1
Bonnefont-Rousselot, D1
Bittar, R1
Chantepie, S1
Orsoni, A1
Bruckert, E1
Chapman, MJ1
Kontush, A1
Danser, AH1
Yeh, CM1
Hsueh, WA1
Neutel, JM1
Leiria, LO1
Sollon, C1
Calixto, MC1
Lintomen, L1
Mónica, FZ1
Anhê, GF1
De Nucci, G1
Zanesco, A1
Grant, AD1
Antunes, E1
Ley, L1
Schumacher, H1
Weber, MA1
Jamerson, K1
Bakris, GL1
Weir, MR1
Zappe, D1
Zhang, Y1
Dahlof, B1
Velazquez, EJ1
Pitt, B1
Takagi, H1
Mizuno, Y1
Yamamoto, H1
Goto, SN1
Umemoto, T1
Ueshiba, H2
Miyachi, Y2
Ersoy, C1
Imamoğlu, S1
Budak, F1
Tuncel, E1
Ertürk, E1
Oral, B1
Ruilope, LM1
Malacco, E1
Khder, Y1
Kandra, A1
Bönner, G1
Heintz, D1
Sanjuliani, AF1
de Abreu, VG1
Francischetti, EA1
Fogari, E1
Ciccarelli, L1
Boye, SW1
Le Breton, S1
Keefe, DL1
Mori, Y1
Itoh, Y1
Tajima, N1
Cosín Aguilar, J1
Hernándiz Martínez, A1
Masramón Morell, X1
Arístegui Urrestarazu, R1
Aguilar Llopis, A1
Zamorano Gómez, JL1
Armada Peláez, B1
Rodríguez Padial, L1
Kagota, S1
Tada, Y1
Kubota, Y1
Nejime, N1
Yamaguchi, Y1
Nakamura, K1
Kunitomo, M1
Shinozuka, K1
Toblli, JE1
Muñoz, MC1
Cao, G1
Mella, J1
Pereyra, L1
Mastai, R1
Rosa, EC1
Zanella, MT1
Kohlmann, NE1
Ferreira, SR1
Plavnik, FL1
Ribeiro, AB1
Kohlmann, O1
Ruvolo, G1
Greco, E1
Speziale, G1
Di Natale, M1
Marino, B1
de Courten, M1
Ferrari, P1
Schneider, M1
Böhlen, L1
Shaw, S1
Riesen, W1
Heynen, G1
Weidmann, P1
Beer, NA1
Jakubowicz, DJ1
Beer, RM1
Nestler, JE1
Tsuboi, K1
Masuo, K1
Mikami, H1
Tuck, ML1

Clinical Trials (8)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
[NCT00000542]Phase 30 participants Interventional1993-08-31Completed
A 16-week Double-blind, Randomized, Multicenter, Force-titration Study to Evaluate the Antihypertensive Efficacy of Valsartan/Hydrochlorothiazide (HCTZ) Therapy Compared to HCTZ Based Therapy in Obese, Hypertensive Patients[NCT00439738]Phase 4412 participants (Actual)Interventional2006-12-31Completed
A 10-week Multicenter,Forced-titration Study Using 24-hr ABPM to Evaluate the Efficacy of Valsartan/Hydrochlorothiazide (HCTZ) Treatment Regimen vs Conventional Treatment Regimen With Amlodipine and Hydrochlorothiazide (HCTZ) in Patients With Stage 2 Hype[NCT00425997]Phase 4480 participants (Anticipated)Interventional2006-12-31Completed
A Prospective, Open-Label, Titration Study to Evaluate the Efficacy and Safety Safety of AZOR in Multiple Subgroups of Hypertensive Subjects Who Are Non-Responders to Anti-Hypertensive Monotherapy[NCT00791258]Phase 4999 participants (Actual)Interventional2008-11-30Completed
A Prospective, Multinational, Multicenter Trial to Compare the Effects of Amlodipine/Benazepril to Benazepril and Hydrochlorothiazide Combined on the Reduction of Cardiovascular Morbidity and Mortality in Patients With High Risk Hypertension[NCT00170950]Phase 311,506 participants (Actual)Interventional2003-10-31Terminated (stopped due to The study was terminated early because of significant efficacy results for the primary endpoint in favor of benazepril/amlodipine treatment.)
A 12-week Randomized Double-blind Parallel Group Study to Evaluate the Efficacy and Safety of the Combination Aliskiren With HCTZ Compared to Irbesartan or Amlodipine With HCTZ or HCTZ Alone in Hypertensive Patients With BMI ≥ 30 kg/m2 Not Adequately Resp[NCT00219115]Phase 3493 participants (Actual)Interventional2005-01-31Completed
Treatment of Essential Hypertension With Rasilez. Evaluation of Different Methods of Blood Pressure Measurements - Efficacy and Safety Evaluation[NCT01060865]Phase 450 participants (Actual)Interventional2010-03-31Terminated (stopped due to The participants signed an old version of the informed consent.)
Molecular - Genetic Alterations in Adipose Tissue After Change in Therapy From ACE Inhibitors to AT1 Receptor Blockers in Patients With Essential Hypertension[NCT01444833]35 participants (Anticipated)Interventional2008-10-31Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change From Baseline in Postprandial Glucose

After a 75 gram anhydrous glucose challenge 2 hours after an oral glucose tolerance test (NCT00439738)
Timeframe: Week 16

,
Interventionmg/dL (Mean)
Baseline visit (0 minutes)Week 16 (0 minutes)Change from baseline to week 16 (0 minutes)Baseline visit (120 minutes)Week 16 (120 minutes)Change from baseline to week 16 (120 minutes)
HCTZ +Amlodipine99.4102.83.4127.7146.518.9
Valsartan/HCTZ (Hydrochlorothiazide)98.098.1-0.5123.9126.32.1

Change From Baseline in Postprandial Insulin

After a 75 gram anhydrous glucose challenge 2 hours after an oral glucose tolerance test (NCT00439738)
Timeframe: Week 16

,
Interventionmg/dL (Mean)
Baseline visit (0 minutes)Week 16 (0 minutes)Change from baseline to week 16 (0 minutes)Baseline visit (120 minutes)Week 16 (120 minutes)Change from baseline to week 16 (120 minute)
HCTZ +Amlodipine20.3723.623.6795.95120.0128.07
Valsartan/HCTZ (Hydrochlorothiazide)19.6623.453.4192.04116.0424.68

Change From Baseline in Postprandial Non-esterified Fatty Acids

After a 75 gram anhydrous glucose challenge 2 hours after an oral glucose tolerance test (NCT00439738)
Timeframe: Week 16

,
Interventionmg/dL (Mean)
Baseline visit (0 minutes)Week 16 (0 minutes)Change from baseline to week 16 (0 minutes)Baseline visit (120 minutes)Week 16 (120 minutes)Change from baseline to week 16 (120 minutes)
HCTZ +Amlodipine0.470.470.000.100.10-0.01
Valsartan/HCTZ (Hydrochlorothiazide)0.450.460.010.110.10-0.01

Change in Mean Sitting Diastolic Blood Pressure (MSDBP)

(NCT00439738)
Timeframe: Baseline to Weeks 4, 8, 12 and 16

,
Interventionmm Hg (Mean)
BaselineWeek 4Week 8Week 12Week 16Change from baseline to week 16
HCTZ +Amlodipine93.687.685.182.880.9-12.7
Valsartan/HCTZ (Hydrochlorothiazide)94.985.781.981.180.8-14.0

Change in Mean Sitting Systolic Blood Pressure (MSSBP)

(NCT00439738)
Timeframe: Baseline to Week 8

,
Interventionmm Hg (Mean)
BaselineWeek 8Change from baseline
HCTZ +Amlodipine159.0137.5-21.5
Valsartan/HCTZ (Hydrochlorothiazide)159.7131.2-28.6

Number of Patients Achieving Blood Pressure (BP) Control by Visit (< 140/90 mm Hg)

Mean sitting systolic blood pressure/mean sitting diastolic blood pressure < 140/90 mm Hg (NCT00439738)
Timeframe: Weeks 4, 8, 12 16 and End of Study (for patients that did not complete the last visit at week 16)

,
Interventionparticipants (Number)
Week 4Week 8Week 12Week 16End of study
HCTZ +Amlodipine69102112140146
Valsartan/HCTZ (Hydrochlorothiazide)91123122124133

Number of Patients Achieving Blood Pressure (BP)Control by Visit (< 130/80 mm Hg)

Mean sitting systolic blood pressure/mean sitting diastolic blood pressure < 130/80 mm Hg (NCT00439738)
Timeframe: Week 4, 8, 12, 16, End of Study (for patients that did not complete the last visit at week 16)

,
Interventionparticipants (Number)
Week 4Week 8Week 12Week 16End of Study
HCTZ +Amlodipine1823466568
Valsartan/HCTZ (Hydrochlorothiazide)3359576268

The Percentage of Patients Who Achieve Seated Systolic Blood Pressure Goal (<140 mm Hg for Non-diabetics and <130 mm Hg for Diabetics) From Baseline to 12 Weeks

(NCT00791258)
Timeframe: baseline to 12 weeks

InterventionPercentage of participants (Number)
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide75.8

The Percentage of Subjects Achieving Seated Diastolic BP Goal (<90 mmHg for Non-diabetics or < 80 mmHg for Subjects With Diabetes) From Baseline to 12 Weeks

(NCT00791258)
Timeframe: baseline to 12 weeks

InterventionPercentage of participants (Number)
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide84.3

Change From Baseline to Week 12 in Ambulatory Systolic and Diastolic Blood Pressure Values

Once the Ambulatory Blood Pressure Monitor (ABPM) has been applied, the dose of medication was taken and the subject wore the ABPM for a period of 24 hours. Daytime is defined as 8 a.m. to 4 p.m. Nighttime is defined as 10 p.m. to 6 a.m. (NCT00791258)
Timeframe: Baseline to 12 weeks

Interventionmm Hg (Mean)
24-hour mean systolic blood pressureMean daytime systolic blood pressureMean nighttime systolic blood pressureSystolic blood pressure - last 2 hours of doseSystolic blood pressure - last 4 hours of doseSystolic blood pressure - last 6 hours of dose24-hour mean diastolic blood pressureMean daytime diastolic blood pressureMean nighttime diastolic blood pressureDiastolic blood pressure - last 2 hours of doseDiastolic blood pressure - last 4 hours of doseDiastolic blood pressure - last 6 hours of dose
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide-14.8-16.3-12.5-13.6-13.0-12.6-9.4-10.6-7.6-8.6-8.0-7.7

Change From Baseline to Week 20 in Ambulatory Systolic and Diastolic Blood Pressure Values

Once the Ambulatory Blood Pressure Monitor (ABPM) has been applied, the dose of medication was taken and the subject wore the ABPM for a period of 24 hours. Daytime is defined as 8 a.m. to 4 p.m. Nighttime is defined as 10 p.m. to 6 a.m. (NCT00791258)
Timeframe: Baseline to 20 weeks

Interventionmm Hg (Mean)
24-hour mean systolic blood pressureMean daytime systolic blood pressureMean nighttime systolic blood pressureSystolic blood pressure - last 2 hours of doseSystolic blood pressure - last 4 hours of doseSystolic blood pressure - last 6 hours of dose24-hour mean diastolic blood pressureMean daytime diastolic blood pressureMean nighttime diastolic blood pressureDiastolic blood pressure - last 2 hours of doseDiastolic blood pressure - last 4 hours of doseDiastolic blood pressure - last 6 hours of dose
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide-21.0-23.2-17.5-19.6-18.2-17.9-13.3-15.0-11.1-12.3-11.6-11.3

Change in Mean Seated Diastolic Blood Pressure From Baseline to 4, 8, 12, 16, 20 Weeks

(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks

Interventionmm Hg (Mean)
4 weeks, N=9758 weeks, N=92912 weeks, N=86516 weeks, N=79720 weeks, N=745
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide-8.1-9.1-11.9-14.6-14.5

Change in Mean Seated Systolic Blood Pressure From Baseline to 4, 8, 12, 16, 20 Weeks

(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks

Interventionmm Hg (Mean)
4 weeks, N=9758 weeks, N=92912 weeks, N=86516 weeks, N=79720 weeks, N=745
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide-14.6-16.6-21.8-26.0-26.8

Percentage of African American/Black Patients Achieving Seated Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks

InterventionPercentage of Participants (Number)
4 weeks: <140/90 mm Hg, N=2304 weeks: <135/80 mm Hg, N=2304 weeks: <130/80 mm Hg, N=2304 weeks: <120/80 mm Hg, N=2308 weeks: <140/90 mm Hg, N=2318 weeks: <135/80 mm Hg, N=2318 weeks: <130/80 mm Hg, N=2328 weeks: <120/80 mm Hg, N=23212 weeks: <140/90mm Hg, N=23212 weeks: <135/80 mm Hg, N=23212 weeks: <130/80 mm Hg, N=23212 weeks: <120/80 mm Hg, N=23216 weeks: <140/90 mm Hg, N=23216 weeks: <135/80 mm Hg, N=23216 weeks: <130/80 mm Hg, N=23216 weeks: <120/80 mm Hg, N=23220 weeks: <140/90 mm Hg, N=23220 weeks: <135/80 mm Hg, N=23220 weeks: <130/80 mm Hg, N=23220 weeks: <120/80 mm Hg, N=232
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide45.714.810.43.955.023.820.810.468.538.435.816.480.649.147.430.686.657.855.239.7

Percentage of African American/Black Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks

InterventionPercentage of Participants (Number)
4 weeks: <90 mm Hg, N=2304 weeks: <85 mm Hg, N=2304 weeks: <80 mm Hg, N=2308 weeks: <90 mm Hg, N=2318 weeks: <85 mm Hg, N=2318 weeks: <80 mm Hg, N=23112 weeks: <90 mm Hg, N=23212 weeks: <85 mm Hg, N=23212 weeks: <80 mm Hg, N=23216 weeks: <90 mm Hg, N=23216 weeks: <85 mm Hg, N=23216 weeks: <80 mm Hg, N=23220 weeks: <90 mm Hg, N=23220 weeks: <85 mm Hg, N=23220 weeks: <80 mm Hg, N=232
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide60.942.219.671.953.730.382.366.045.392.276.355.294.880.661.2

Percentage of African American/Black Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks

(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks

InterventionPercentage of Participants (Number)
4 weeks: ≤ 10 mm Hg, N=2304 weeks: >10 and ≤ 15 mm Hg, N=2304 weeks: >15 and ≤ 20 mm Hg, N=2304 weeks: >20 mm Hg, N=2308 weeks: ≤ 10 mm Hg, N=2208 weeks: >10 and ≤ 15 mm Hg, N=2208 weeks: >15 and ≤ 20 mm Hg, N=2208 weeks: >20 mm Hg, N=22012 weeks: ≤ 10 mm Hg, N=20812 weeks: >10 and ≤15 mm Hg, N=20812 weeks: >15 and ≤ 20 mm Hg, N=20812 weeks: >20 mm Hg, N=20816 weeks: ≤ 10 mm Hg, N=19916 weeks: >10 and ≤ 15 mm Hg, N=19916 weeks: >15 and ≤ 20 mm Hg, N=19916 weeks: >20 mm Hg, N=19920 weeks: ≤ 10 mm Hg, N=18920 weeks: >10 and ≤ 15 mm Hg, N=18920 weeks: >15 and ≤ 20 mm Hg, N=18920 weeks: >20 mm Hg, N=189
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide70.017.87.94.466.815.010.97.354.821.212.012.038.719.623.118.636.019.620.623.8

Percentage of African American/Black Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks

InterventionPercentage of Participants (Number)
4 weeks: <140 mm Hg, N=2304 weeks: <135 mm Hg, N=2304 weeks: <130 mm Hg, N=2304 weeks: <120 mm Hg, N=2308 weeks: <140 mm Hg, N=2318 weeks: <135 mm Hg, N=2318 weeks: <130 mm Hg, N=2318 weeks: <120 mm Hg, N=23112 weeks: <140 mm Hg, N=23212 weeks: <135 mm Hg, N=23212 weeks: <130 mm Hg, N=23212 weeks: <120 mm Hg, N=23216 weeks: <140 mm Hg, N=23216 weeks: <135 mm Hg, N=23216 weeks: <130 mm Hg, N=23216 weeks: <120 mm Hg, N=23220 weeks: <140 mm Hg, N=23220 weeks: <135 mm Hg, N=23220 weeks: <130 mm Hg, N=23220 weeks: <120 mm Hg, N=232
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide51.734.419.65.762.344.633.813.076.359.147.019.884.971.161.234.191.080.671.144.4

Percentage of African American/Black Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks

(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks

InterventionPercentage of Participants (Number)
4 weeks: ≤ 15 mm Hg, N=2304 weeks: >15 and ≤ 30 mm Hg, N=2304 weeks: >30 and ≤ 45 mm Hg, N=2304 weeks: >45 mm Hg, N=2308 weeks: ≤ 15 mm Hg, N=2208 weeks: >15 and ≤ 30 mm Hg, N=2208 weeks: >30 and ≤ 45 mm Hg, N=2208 weeks: >45 mm Hg, N=22012 weeks: ≤ 15 mm Hg, N=20812 weeks: >15 and ≤ 30 mm Hg, N=20812 weeks: >30 and ≤ 45 mm Hg, N=20812 weeks: >45 mm Hg, N=20816 weeks: ≤ 15 mm Hg, N=19916 weeks: >15 and ≤ 30 mm Hg, N=19916 weeks: >30 and ≤ 45 mm Hg, N=19916 weeks: >45 mm Hg, N=19920 weeks: ≤ 15 mm Hg, N=18920 weeks: >15 and ≤ 30 mm Hg, N=18920 weeks: >30 and ≤ 45 mm Hg, N=18920 weeks: >45 mm Hg, N=189
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide60.032.27.40.453.638.27.30.938.941.816.42.930.737.225.17.024.337.629.68.5

Percentage of Asain Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks

InterventionPercentage of Participants (Number)
4 weeks: <90 mm Hg, N=1284 weeks: <85 mm Hg, N=1284 weeks: <80 mm Hg, N=1288 weeks: <90 mm Hg, N=1288 weeks: <85 mm Hg, N=1288 weeks: <80 mm Hg, N=12812 weeks: <90 mm Hg, N=12812 weeks: <85 mm Hg, N=12812 weeks: <80 mm Hg, N=12816 weeks: <90 mm Hg, N=12816 weeks: <85 mm Hg, N=12816 weeks: <80 mm Hg, N=12820 weeks: <90 mm Hg, N=12820 weeks: <85 mm Hg, N=12820 weeks: <80 mm Hg, N=128
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide83.669.545.389.179.760.295.387.571.196.993.082.096.993.085.2

Percentage of Asian Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks

(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks

InterventionPercentage of Participants (Number)
4 weeks: ≤ 10 mm Hg, N=1264 weeks: >10 and ≤ 15 mm Hg, N=1264 weeks: >15 and ≤ 20 mm Hg, N=1264 weeks: >20 mm Hg, N=1268 weeks: ≤ 10 mm Hg, N=1238 weeks: >10 and ≤ 15 mm Hg, N=1238 weeks: >15 and ≤ 20 mm Hg, N=1238 weeks: >20 mm Hg, N=12312 weeks: ≤ 10 mm Hg, N=12012 weeks: >10 and ≤15 mm Hg, N=12012 weeks: >15 and ≤ 20 mm Hg, N=12012 weeks: >20 mm Hg, N=12016 weeks: ≤ 10 mm Hg, N=11216 weeks: >10 and ≤ 15 mm Hg, N=11216 weeks: >15 and ≤ 20 mm Hg, N=11216 weeks: >20 mm Hg, N=11220 weeks: ≤ 10 mm Hg, N=10520 weeks: >10 and ≤ 15 mm Hg, N=10520 weeks: >15 and ≤ 20 mm Hg, N=10520 weeks: >20 mm Hg, N=105
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide47.626.213.512.738.224.422.015.533.325.819.221.727.717.020.534.836.216.218.129.5

Percentage of Asian Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks

InterventionPercentage of Participants (Number)
4 weeks: <140 mm Hg, N=1284 weeks: <135 mm Hg, N=1284 weeks: <130 mm Hg, N=1284 weeks: <120 mm Hg, N=1288 weeks: <140 mm Hg, N=1288 weeks: <135 mm Hg, N=1288 weeks: <130 mm Hg, N=1288 weeks: <120 mm Hg, N=12812 weeks: <140 mm Hg, N=12812 weeks: <135 mm Hg, N=12812 weeks: <130 mm Hg, N=12812 weeks: <120 mm Hg, N=12816 weeks: <140 mm Hg, N=12816 weeks: <135 mm Hg, N=12816 weeks: <130 mm Hg, N=12816 weeks: <120 mm Hg, N=12820 weeks: <140 mm Hg, N=12820 weeks: <135 mm Hg, N=12820 weeks: <130 mm Hg, N=12820 weeks: <120 mm Hg, N=128
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide64.851.635.211.776.667.251.625.089.178.966.438.395.389.881.347.797.793.085.951.6

Percentage of Asian Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks

(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks

InterventionPercentage of Participants (Number)
4 weeks: ≤ 15 mm Hg, N=1264 weeks: >15 and ≤ 30 mm Hg, N=1264 weeks: >30 and ≤ 45 mm Hg, N=1264 weeks: >45 mm Hg, N=1268 weeks: ≤ 15 mm Hg, N=1238 weeks: >15 and ≤ 30 mm Hg, N=1238 weeks: >30 and ≤ 45 mm Hg, N=1238 weeks: >45 mm Hg, N=12312 weeks: ≤ 15 mm Hg, N=12012 weeks: >15 and ≤ 30 mm Hg, N=12012 weeks: >30 and ≤ 45 mm Hg, N=12012 weeks: >45 mm Hg, N=12016 weeks: ≤ 15 mm Hg, N=11216 weeks: >15 and ≤ 30 mm Hg, N=11216 weeks: >30 and ≤ 45 mm Hg, N=11216 weeks: >45 mm Hg, N=11220 weeks: ≤ 15 mm Hg, N=10520 weeks: >15 and ≤ 30 mm Hg, N=10520 weeks: >30 and ≤ 45 mm Hg, N=10520 weeks: >45 mm Hg, N=105
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide43.738.115.92.440.735.822.01.628.339.227.55.020.536.631.311.629.528.633.38.6

Percentage of Elderly Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks

InterventionPercentage of Participants (Number)
4 weeks: <90 mm Hg, N=2274 weeks: <85 mm Hg, N=2274 weeks: <80 mm Hg, N=2278 weeks: <90 mm Hg, N=2278 weeks: <85 mm Hg, N=2278 weeks: <80 mm Hg, N=22712 weeks: <90 mm Hg, N=22712 weeks: <85 mm Hg, N=22712 weeks: <80 mm Hg, N=22716 weeks: <90 mm Hg, N=22716 weeks: <85 mm Hg, N=22716 weeks: <80 mm Hg, N=22720 weeks: <90 mm Hg, N=22720 weeks: <85 mm Hg, N=22720 weeks: <80 mm Hg, N=227
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide88.176.758.292.183.771.897.492.180.298.794.388.698.795.290.3

Percentage of Elderly Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks

(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks

InterventionPercentage of Participants (Number)
4 weeks: ≤ 10 mm Hg, N=2244 weeks: >10 and ≤ 15 mm Hg, N=2244 weeks: >15 and ≤ 20 mm Hg, N=2244 weeks: >20 mm Hg, N=2248 weeks: ≤ 10 mm Hg, N=2178 weeks: >10 and ≤ 15 mm Hg, N=2178 weeks: >15 and ≤ 20 mm Hg, N=2178 weeks: >20 mm Hg, N=21712 weeks: ≤ 10 mm Hg, N=19912 weeks: >10 and ≤15 mm Hg, N=19912 weeks: >15 and ≤ 20 mm Hg, N=19912 weeks: >20 mm Hg, N=19916 weeks: ≤ 10 mm Hg, N=17916 weeks: >10 and ≤ 15 mm Hg, N=17916 weeks: >15 and ≤ 20 mm Hg, N=17916 weeks: >20 mm Hg, N=17920 weeks: ≤ 10 mm Hg, N=16620 weeks: >10 and ≤ 15 mm Hg, N=16620 weeks: >15 and ≤ 20 mm Hg, N=16620 weeks: >20 mm Hg, N=166
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide63.820.59.46.357.119.814.38.845.225.115.614.127.425.122.924.634.920.524.120.5

Percentage of Elderly Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks

InterventionPercentage of Participants (Number)
4 weeks: <140 mm Hg, N=2274 weeks: <135 mm Hg, N=2274 weeks: <130 mm Hg, N=2274 weeks: <120 mm Hg, N=2278 weeks: <140 mm Hg, N=2278 weeks: <135 mm Hg, N=2278 weeks: <130 mm Hg, N=2278 weeks: <120 mm Hg, N=22712 weeks: <140 mm Hg, N=22712 weeks: <135 mm Hg, N=22712 weeks: <130 mm Hg, N=22712 weeks: <120 mm Hg, N=22716 weeks: <140 mm Hg, N=22716 weeks: <135 mm Hg, N=22716 weeks: <130 mm Hg, N=22716 weeks: <120 mm Hg, N=22720 weeks: <140 mm Hg, N=22720 weeks: <135 mm Hg, N=22720 weeks: <130 mm Hg, N=22720 weeks: <120 mm Hg, N=227
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide52.037.923.49.767.057.743.618.180.670.056.828.687.779.770.943.691.685.978.950.7

Percentage of Elderly Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks

(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks

InterventionPercentage of Participants (Number)
4 weeks: ≤ 15 mm Hg, N=2244 weeks: >15 and ≤ 30 mm Hg, N=2244 weeks: >30 and ≤ 45 mm Hg, N=2244 weeks: >45 mm Hg, N=2248 weeks: ≤ 15 mm Hg, N=2178 weeks: >15 and ≤ 30 mm Hg, N=2178 weeks: >30 and ≤ 45 mm Hg, N=2178 weeks: >45 mm Hg, N=21712 weeks: ≤ 15 mm Hg, N=19912 weeks: >15 and ≤ 30 mm Hg, N=19912 weeks: >30 and ≤ 45 mm Hg, N=19912 weeks: >45 mm Hg, N=19916 weeks: ≤ 15 mm Hg, N=17916 weeks: >15 and ≤ 30 mm Hg, N=17916 weeks: >30 and ≤ 45 mm Hg, N=17916 weeks: >45 mm Hg, N=17920 weeks: ≤ 15 mm Hg, N=16620 weeks: >15 and ≤ 30 mm Hg, N=16620 weeks: >30 and ≤ 45 mm Hg, N=16620 weeks: >45 mm Hg, N=166
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide47.340.211.21.342.937.816.62.826.646.724.62.017.932.439.710.114.537.438.010.2

Percentage of Hispanic Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks

InterventionPercentage of Participants (Number)
4 weeks: <90 mm Hg, N=984 weeks: <85 mm Hg, N=984 weeks: <80 mm Hg, N=988 weeks: <90 mm Hg, N=1008 weeks: <85 mm Hg, N=1008 weeks: <80 mm Hg, N=10012 weeks: <90 mm Hg, N=10012 weeks: <85 mm Hg, N=10012 weeks: <80 mm Hg, N=10016 weeks: <90 mm Hg, N=10016 weeks: <85 mm Hg, N=10016 weeks: <80 mm Hg, N=10020 weeks: <90 mm Hg, N=10020 weeks: <85 mm Hg, N=10020 weeks: <80 mm Hg, N=100
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide66.353.134.785.070.048.092.078.062.096.090.075.096.090.075.0

Percentage of Hispanic Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks

(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks

InterventionPercentage of Participants (Number)
4 weeks: ≤ 10 mm Hg, N=984 weeks: >10 and ≤ 15 mm Hg, N=984 weeks: >15 and ≤ 20 mm Hg, N=984 weeks: >20 mm Hg, N=988 weeks: ≤ 10 mm Hg, N=918 weeks: >10 and ≤ 15 mm Hg, N=918 weeks: >15 and ≤ 20 mm Hg, N=918 weeks: >20 mm Hg, N=9112 weeks: ≤ 10 mm Hg, N=8312 weeks: >10 and ≤15 mm Hg, N=8312 weeks: >15 and ≤ 20 mm Hg, N=8312 weeks: >20 mm Hg, N=8316 weeks: ≤ 10 mm Hg, N=7516 weeks: >10 and ≤ 15 mm Hg, N=7516 weeks: >15 and ≤ 20 mm Hg, N=7516 weeks: >20 mm Hg, N=7520 weeks: ≤ 10 mm Hg, N=7120 weeks: >10 and ≤ 15 mm Hg, N=7120 weeks: >15 and ≤ 20 mm Hg, N=7120 weeks: >20 mm Hg, N=71
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide65.316.38.210.252.818.714.314.341.020.514.524.130.725.316.028.031.012.726.829.6

Percentage of Hispanic Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks

InterventionPercentage of Participants (Number)
4 weeks: <140 mm Hg, N=984 weeks: <135 mm Hg, N=984 weeks: <130 mm Hg, N=984 weeks: <120 mm Hg, N=988 weeks: <140 mm Hg, N=1008 weeks: <135 mm Hg, N=1008 weeks: <130 mm Hg, N=1008 weeks: <120 mm Hg, N=10012 weeks: <140 mm Hg, N=10012 weeks: <135 mm Hg, N=10012 weeks: <130 mm Hg, N=10012 weeks: <120 mm Hg, N=10016 weeks: <140 mm Hg, N=10016 weeks: <135 mm Hg, N=10016 weeks: <130 mm Hg, N=10016 weeks: <120 mm Hg, N=10020 weeks: <140 mm Hg, N=10020 weeks: <135 mm Hg, N=10020 weeks: <130 mm Hg, N=10020 weeks: <120 mm Hg, N=100
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide55.139.831.610.264.051.041.015.077.067.054.030.084.077.066.037.088.083.072.041.0

Percentage of Hispanic Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks

(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks

InterventionPercentage of Participants (Number)
4 weeks: ≤ 15 mm Hg, N=984 weeks: >15 and ≤ 30 mm Hg, N=984 weeks: >30 and ≤ 45 mm Hg, N=984 weeks: >45 mm Hg, N=988 weeks: ≤ 15 mm Hg, N=918 weeks: >15 and ≤ 30 mm Hg, N=918 weeks: >30 and ≤ 45 mm Hg, N=918 weeks: >45 mm Hg, N=9112 weeks: ≤ 15 mm Hg, N=8312 weeks: >15 and ≤ 30 mm Hg, N=8312 weeks: >30 and ≤ 45 mm Hg, N=8312 weeks: >45 mm Hg, N=8316 weeks: ≤ 15 mm Hg, N=7516 weeks: >15 and ≤ 30 mm Hg, N=7516 weeks: >30 and ≤ 45 mm Hg, N=7516 weeks: >45 mm Hg, N=7520 weeks: ≤ 15 mm Hg, N=7120 weeks: >15 and ≤ 30 mm Hg, N=7120 weeks: >30 and ≤ 45 mm Hg, N=7120 weeks: >45 mm Hg, N=71
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide50.037.87.15.142.944.09.93.331.336.125.37.222.736.034.76.723.933.833.88.5

Percentage of Obese Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks

InterventionPercentage of Participants (Number)
4 weeks: <90 mm Hg, N=4974 weeks: <85 mm Hg, N=4974 weeks: <80 mm Hg, N=4978 weeks: <90 mm Hg, N=4978 weeks: <85 mm Hg, N=5008 weeks: <80 mm Hg, N=50012 weeks: <90 mm Hg, N=50012 weeks: <85 mm Hg, N=50012 weeks: <80 mm Hg, N=50016 weeks: <90 mm Hg, N=50016 weeks: <85 mm Hg, N=50016 weeks: <80 mm Hg, N=50020 weeks: <90 mm Hg, N=50020 weeks: <85 mm Hg, N=50020 weeks: <80 mm Hg, N=500
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide63.246.326.077.259.438.886.669.848.493.280.460.494.683.867.6

Percentage of Obese Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks

(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks

InterventionPercentage of Participants (Number)
4 weeks: ≤ 10 mm Hg, N=4954 weeks: >10 and ≤ 15 mm Hg, N=4954 weeks: >15 and ≤ 20 mm Hg, N=4954 weeks: >20 mm Hg, N=4958 weeks: ≤ 10 mm Hg, N=4688 weeks: >10 and ≤ 15 mm Hg, N=4688 weeks: >15 and ≤ 20 mm Hg, N=4688 weeks: >20 mm Hg, N=46812 weeks: ≤ 10 mm Hg, N=43612 weeks: >10 and ≤15 mm Hg, N=43612 weeks: >15 and ≤ 20 mm Hg, N=43612 weeks: >20 mm Hg, N=43616 weeks: ≤ 10 mm Hg, N=40016 weeks: >10 and ≤ 15 mm Hg, N=40016 weeks: >15 and ≤ 20 mm Hg, N=40016 weeks: >20 mm Hg, N=40020 weeks: ≤ 10 mm Hg, N=37920 weeks: >10 and ≤ 15 mm Hg, N=37920 weeks: >15 and ≤ 20 mm Hg, N=37920 weeks: >20 mm Hg, N=379
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide67.517.88.56.359.419.913.07.748.922.516.112.633.323.019.024.831.918.722.426.9

Percentage of Obese Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks

InterventionPercentage of Participants (Number)
4 weeks: <140 mm Hg, N=4974 weeks: <135 mm Hg, N=4974 weeks: <130 mm Hg, N=4974 weeks: <120 mm Hg, N=4978 weeks: <140 mm Hg, N=5008 weeks: <135 mm Hg, N=5008 weeks: <130 mm Hg, N=5008 weeks: <120 mm Hg, N=50012 weeks: <140 mm Hg, N=50012 weeks: <135 mm Hg, N=50012 weeks: <130 mm Hg, N=50012 weeks: <120 mm Hg, N=50016 weeks: <140 mm Hg, N=50016 weeks: <135 mm Hg, N=50016 weeks: <130 mm Hg, N=50016 weeks: <120 mm Hg, N=50020 weeks: <140 mm Hg, N=50020 weeks: <135 mm Hg, N=50020 weeks: <130 mm Hg, N=50020 weeks: <120 mm Hg, N=500
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide51.337.223.37.963.249.237.013.876.661.649.223.285.875.663.634.690.282.672.243.0

Percentage of Obese Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks

(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks

InterventionPercentage of Participants (Number)
4 weeks: ≤ 15 mm Hg, N=4954 weeks: >15 and ≤ 30 mm Hg, N=4954 weeks: >30 and ≤ 45 mm Hg, N=4954 weeks: >45 mm Hg, N=4958 weeks: ≤ 15 mm Hg, N=4688 weeks: >15 and ≤ 30 mm Hg, N=4688 weeks: >30 and ≤ 45 mm Hg, N=4688 weeks: >45 mm Hg, N=46812 weeks: ≤ 15 mm Hg, N=43612 weeks: >15 and ≤ 30 mm Hg, N=43612 weeks: >30 and ≤ 45 mm Hg, N=43612 weeks: >45 mm Hg, N=43616 weeks: ≤ 15 mm Hg, N=40016 weeks: >15 and ≤ 30 mm Hg, N=40016 weeks: >30 and ≤ 45 mm Hg, N=40016 weeks: >45 mm Hg, N=40020 weeks: ≤ 15 mm Hg, N=37920 weeks: >15 and ≤ 30 mm Hg, N=37920 weeks: >30 and ≤ 45 mm Hg, N=37920 weeks: >45 mm Hg, N=379
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide56.035.28.50.452.435.910.31.537.842.417.42.527.836.027.58.820.637.533.38.7

Percentage of Participants Achieving the Mean 24-hour Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 12 Weeks

Once the Ambulatory Blood Pressure Monitor (ABPM) has been applied, the dose of medication was taken and the subject wore the ABPM for a period of 24 hours. (NCT00791258)
Timeframe: Baseline to 12 weeks

InterventionPercentage of participants (Number)
24-hour mean systolic blood pressure <140 mmHg24-hour mean systolic blood pressure <135 mmHg24-hour mean systolic blood pressure <130 mmHg24-hour mean systolic blood pressure <120 mmHg24-hour mean diastolic blood pressure <90 mmHg24-hour mean diastolic blood pressure <85 mmHg24-hour mean diastolic blood pressure <80 mmHg24-hour mean blood pressure <140/90 mmHg24-hour mean blood pressure <135/95 mmHg24-hour mean blood pressure <135/80 mmHg24-hour mean blood pressure <130/80 mmHg24-hour mean blood pressure <125/75 mmHg24-hour mean blood pressure <120/80 mmHg24-hour mean blood pressure <120/70 mmHg
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide95.690.479.947.298.796.184.794.389.180.373.452.445.927.5

Percentage of Participants Achieving the Mean 24-hour Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 20 Weeks

Once the Ambulatory Blood Pressure Monitor (ABPM) has been applied, the dose of medication was taken and the subject wore the ABPM for a period of 24 hours. (NCT00791258)
Timeframe: Baseline to 20 weeks

InterventionPercentage of participants (Number)
24-hour mean systolic blood pressure <140 mmHg24-hour mean systolic blood pressure <135 mmHg24-hour mean systolic blood pressure <130 mmHg24-hour mean systolic blood pressure <120 mmHg24-hour mean diastolic blood pressure <90 mmHg24-hour mean diastolic blood pressure <85 mmHg24-hour mean diastolic blood pressure <80 mmHg24-hour mean blood pressure <140/90 mmHg24-hour mean blood pressure <135/95 mmHg24-hour mean blood pressure <135/80 mmHg24-hour mean blood pressure <130/80 mmHg24-hour mean blood pressure <125/75 mmHg24-hour mean blood pressure <120/80 mmHg24-hour mean blood pressure <120/70 mmHg
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide99.597.594.570.4100.097.593.099.596.092.590.575.470.455.3

Percentage of Participants Achieving the Mean Daytime Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 12 Weeks

Once the Ambulatory Blood Pressure Monitor (ABPM) has been applied, the dose of medication was taken and the subject wore the ABPM for a period of 24 hours. Daytime is defined as 8AM - 4PM. (NCT00791258)
Timeframe: Baseline to 12 weeks

InterventionPercentage of participants (Number)
Daytime mean systolic blood pressure <140 mmHgDaytime mean systolic blood pressure <135 mmHgDaytime mean systolic blood pressure <130 mmHgDaytime mean systolic blood pressure <120 mmHgDaytime mean diastolic blood pressure <90 mmHgDaytime mean diastolic blood pressure <85 mmHgDaytime mean diastolic blood pressure <80 mmHgDaytime mean blood pressure <140/90 mmHgDaytime mean blood pressure <135/95 mmHgDaytime mean blood pressure <135/80 mmHgDaytime mean blood pressure <130/80 mmHgDaytime mean blood pressure <125/75 mmHgDaytime mean blood pressure <120/80 mmHgDaytime mean blood pressure <120/70 mmHg
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide88.279.966.428.895.683.065.586.972.961.153.331.927.913.1

Percentage of Participants Achieving the Mean Daytime Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 20 Weeks

Once the Ambulatory Blood Pressure Monitor (ABPM) has been applied, the dose of medication was taken and the subject wore the ABPM for a period of 24 hours. Daytime is defined as 8AM - 4PM. (NCT00791258)
Timeframe: Baseline to 20 weeks

InterventionPercentage of participants (Number)
Daytime mean systolic blood pressure <140 mmHgDaytime mean systolic blood pressure <135 mmHgDaytime mean systolic blood pressure <130 mmHgDaytime mean systolic blood pressure <120 mmHgDaytime mean diastolic blood pressure <90 mmHgDaytime mean diastolic blood pressure <85 mmHgDaytime mean diastolic blood pressure <80 mmHgDaytime mean blood pressure <140/90 mmHgDaytime mean blood pressure <135/95 mmHgDaytime mean blood pressure <135/80 mmHgDaytime mean blood pressure <130/80 mmHgDaytime mean blood pressure <125/75 mmHgDaytime mean blood pressure <120/80 mmHgDaytime mean blood pressure <120/70 mmHg
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide96.593.583.951.898.592.583.995.088.481.977.456.851.333.2

Percentage of Participants Achieving the Mean Nighttime Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 12 Weeks

Once the Ambulatory Blood Pressure Monitor (ABPM) has been applied, the dose of medication was taken and the subject wore the ABPM for a period of 24 hours. Nighttime is defined as 10p.m. - 6 a.m. (NCT00791258)
Timeframe: Baseline to 12 weeks

InterventionPercentage of participants (Number)
Nighttime mean systolic blood pressure <140 mmHgNighttime mean systolic blood pressure <135 mmHgNighttime mean systolic blood pressure <130 mmHgNighttime mean systolic blood pressure <120 mmHgNighttime mean diastolic blood pressure <90 mmHgNighttime mean diastolic blood pressure <85 mmHgNighttime mean diastolic blood pressure <80 mmHgNighttime mean blood pressure <140/90 mmHgNighttime mean blood pressure <135/95 mmHgNighttime mean blood pressure <135/80 mmHgNighttime mean blood pressure <130/80 mmHgNighttime mean blood pressure <125/75 mmHgNighttime mean blood pressure <120/80 mmHgNighttime mean blood pressure <120/70 mmHg
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide97.894.392.674.799.698.394.897.493.490.889.177.774.262.0

Percentage of Participants Achieving the Mean Nighttime Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 20 Weeks

Once the Ambulatory Blood Pressure Monitor (ABPM) has been applied, the dose of medication was taken and the subject wore the ABPM for a period of 24 hours. Nighttime is defined as 10 p.m. - 6 a.m. (NCT00791258)
Timeframe: Baseline to 20 weeks

InterventionPercentage of participants (Number)
Nighttime mean systolic blood pressure <140 mmHgNighttime mean systolic blood pressure <135 mmHgNighttime mean systolic blood pressure <130 mmHgNighttime mean systolic blood pressure <120 mmHgNighttime mean diastolic blood pressure <90 mmHgNighttime mean diastolic blood pressure <85 mmHgNighttime mean diastolic blood pressure <80 mmHgNighttime mean blood pressure <140/90 mmHgNighttime mean blood pressure <135/95 mmHgNighttime mean blood pressure <135/80 mmHgNighttime mean blood pressure <130/80 mmHgNighttime mean blood pressure <125/75 mmHgNighttime mean blood pressure <120/80 mmHgNighttime mean blood pressure <120/70 mmHg
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide99.599.597.586.499.598.596.099.098.596.095.088.985.978.9

Percentage of Participants Previously on a Beta Blocker Achieving the Blood Pressure Goals From Baseline to 12 Weeks

(NCT00791258)
Timeframe: Baseline to 12 weeks

InterventionPercentage of participants (Number)
Systolic blood pressure <140 mmHgSystolic blood pressure <135 mmHgSystolic blood pressure <130 mmHgSystolic blood pressure <120 mmHgDiastolic blood pressure <90 mmHgDiastolic blood pressure <85 mmHgDiastolic blood pressure <80 mmHgBlood pressure <140/90 mmHgBlood pressure <135/80 mmHgBlood pressure <130/80 mmHgBlood pressure <120/80 mmHg
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide88.575.262.033.694.783.261.186.755.849.629.2

Percentage of Participants Previously on a Beta Blocker Achieving the Blood Pressure Goals From Baseline to 20 Weeks

(NCT00791258)
Timeframe: Baseline to 20 weeks

InterventionPercentage of participants (Number)
Systolic blood pressure <140 mmHgSystolic blood pressure <135 mmHgSystolic blood pressure <130 mmHgSystolic blood pressure <120 mmHgDiastolic blood pressure <90 mmHgDiastolic blood pressure <85 mmHgDiastolic blood pressure <80 mmHgBlood pressure <140/90 mmHgBlood pressure <135/80 mmHgBlood pressure <130/80 mmHgBlood pressure <120/80 mmHg
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide93.887.679.747.898.289.477.092.974.369.943.4

Percentage of Participants Previously on a Dihydropyridine Calcium Channel Blocker Achieving the Blood Pressure Goals From Baseline to 12 Weeks

(NCT00791258)
Timeframe: Baseline to 12 weeks

InterventionPercentage of participants (Number)
Systolic blood pressure <140 mmHgSystolic blood pressure <135 mmHgSystolic blood pressure <130 mmHgSystolic blood pressure <120 mmHgDiastolic blood pressure <90 mmHgDiastolic blood pressure <85 mmHgDiastolic blood pressure <80 mmHgBlood pressure <140/90 mmHgBlood pressure <135/80 mmHgBlood pressure <130/80 mmHgBlood pressure <120/80 mmHg
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide73.559.047.918.886.372.748.768.440.234.216.2

Percentage of Participants Previously on a Dihydropyridine Calcium Channel Blocker Achieving the Blood Pressure Goals From Baseline to 20 Weeks

(NCT00791258)
Timeframe: Baseline to 20 weeks

InterventionPercentage of participants (Number)
Systolic blood pressure <140 mmHgSystolic blood pressure <135 mmHgSystolic blood pressure <130 mmHgSystolic blood pressure <120 mmHgDiastolic blood pressure <90 mmHgDiastolic blood pressure <85 mmHgDiastolic blood pressure <80 mmHgBlood pressure <140/90 mmHgBlood pressure <135/80 mmHgBlood pressure <130/80 mmHgBlood pressure <120/80 mmHg
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide89.783.869.241.091.585.569.285.564.159.836.8

Percentage of Participants Previously on a Diuretic Achieving the Blood Pressure Goals From Baseline to 12 Weeks

(NCT00791258)
Timeframe: Baseline to 12 weeks

InterventionPercentage of participants (Number)
Systolic blood pressure <140 mmHgSystolic blood pressure <135 mmHgSystolic blood pressure <130 mmHgSystolic blood pressure <120 mmHgDiastolic blood pressure <90 mmHgDiastolic blood pressure <85 mmHgDiastolic blood pressure <80 mmHgBlood pressure <140/90 mmHgBlood pressure <135/80 mmHgBlood pressure <130/80 mmHgBlood pressure <120/80 mmHg
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide92.882.578.351.294.686.871.788.667.565.148.2

Percentage of Participants Previously on a Diuretic Achieving the Blood Pressure Goals From Baseline to 20 Weeks

(NCT00791258)
Timeframe: Baseline to 20 weeks

InterventionPercentage of participants (Number)
Systolic blood pressure <140 mmHgSystolic blood pressure <135 mmHgSystolic blood pressure <130 mmHgSystolic blood pressure <120 mmHgDiastolic blood pressure <90 mmHgDiastolic blood pressure <85 mmHgDiastolic blood pressure <80 mmHgBlood pressure <140/90 mmHgBlood pressure <135/80 mmHgBlood pressure <130/80 mmHgBlood pressure <120/80 mmHg
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide92.882.578.351.294.686.871.788.667.565.148.2

Percentage of Participants Previously on a Nondihydropyridine Calcium Channel Blocker Achieving the Blood Pressure Goals From Baseline to 12 Weeks

(NCT00791258)
Timeframe: Baseline to 12 weeks

InterventionPercentage of participants (Number)
Systolic blood pressure <140 mmHgSystolic blood pressure <135 mmHgSystolic blood pressure <130 mmHgSystolic blood pressure <120 mmHgDiastolic blood pressure <90 mmHgDiastolic blood pressure <85 mmHgDiastolic blood pressure <80 mmHgBlood pressure <140/90 mmHgBlood pressure <135/80 mmHgBlood pressure <130/80 mmHgBlood pressure <120/80 mmHg
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide100.090.075.025.0100.095.075.0100.070.065.020.0

Percentage of Participants Previously on a Nondihydropyridine Calcium Channel Blocker Achieving the Blood Pressure Goals From Baseline to 20 Weeks

(NCT00791258)
Timeframe: Baseline to 20 weeks

InterventionPercentage of participants (Number)
Systolic blood pressure <140 mmHgSystolic blood pressure <135 mmHgSystolic blood pressure <130 mmHgSystolic blood pressure <120 mmHgDiastolic blood pressure <90 mmHgDiastolic blood pressure <85 mmHgDiastolic blood pressure <80 mmHgBlood pressure <140/90 mmHgBlood pressure <135/80 mmHgBlood pressure <130/80 mmHgBlood pressure <120/80 mmHg
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide100.0100.095.045.0100.095.095.0100.095.095.040.0

Percentage of Participants Previously on an Angiotensin Converting Enzyme Inhibitor Achieving the Blood Pressure Goals From Baseline to 12 Weeks

(NCT00791258)
Timeframe: Baseline to 12 weeks

InterventionPercentage of participants (Number)
Systolic blood pressure <140 mmHgSystolic blood pressure <135 mmHgSystolic blood pressure <130 mmHgSystolic blood pressure <120 mmHgDiastolic blood pressure <90 mmHgDiastolic blood pressure <85 mmHgDiastolic blood pressure <80 mmHgBlood pressure <140/90 mmHgBlood pressure <135/80 mmHgBlood pressure <130/80 mmHgBlood pressure <120/80 mmHg
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide81.369.353.031.594.480.664.378.552.743.527.9

Percentage of Participants Previously on an Angiotensin Converting Enzyme Inhibitor Achieving the Blood Pressure Goals From Baseline to 20 Weeks

(NCT00791258)
Timeframe: Baseline to 20 weeks

InterventionPercentage of participants (Number)
Systolic blood pressure <140 mmHgSystolic blood pressure <135 mmHgSystolic blood pressure <130 mmHgSystolic blood pressure <120 mmHgDiastolic blood pressure <90 mmHgDiastolic blood pressure <85 mmHgDiastolic blood pressure <80 mmHgBlood pressure <140/90 mmHgBlood pressure <135/80 mmHgBlood pressure <130/80 mmHgBlood pressure <120/80 mmHg
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide91.584.571.447.498.289.878.590.571.061.544.5

Percentage of Participants Previously on an Angiotensin II Receptor Blocker Achieving the Blood Pressure Goals From Baseline to 12 Weeks

(NCT00791258)
Timeframe: Baseline to 12 weeks

InterventionPercentage of participants (Number)
Systolic blood pressure <140 mmHgSystolic blood pressure <135 mmHgSystolic blood pressure <130 mmHgSystolic blood pressure <120 mmHgDiastolic blood pressure <90 mmHgDiastolic blood pressure <85 mmHgDiastolic blood pressure <80 mmHgBlood pressure <140/90 mmHgBlood pressure <135/80 mmHgBlood pressure <130/80 mmHgBlood pressure <120/80 mmHg
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide80.869.256.026.189.776.959.076.152.646.223.1

Percentage of Participants Previously on an Angiotensin II Receptor Blocker Achieving the Blood Pressure Goals From Baseline to 20 Weeks

(NCT00791258)
Timeframe: Baseline to 20 weeks

InterventionPercentage of participants (Number)
Systolic blood pressure <140 mmHgSystolic blood pressure <135 mmHgSystolic blood pressure <130 mmHgSystolic blood pressure <120 mmHgDiastolic blood pressure <90 mmHgDiastolic blood pressure <85 mmHgDiastolic blood pressure <80 mmHgBlood pressure <140/90 mmHgBlood pressure <135/80 mmHgBlood pressure <130/80 mmHgBlood pressure <120/80 mmHg
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide92.387.279.547.496.689.374.890.670.165.044.0

Percentage of Patients Achieving Seated Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks

InterventionPercentage of Participants (Number)
4 weeks: <140/90 mm Hg, N=9754 weeks: <135/80 mm Hg, N=9754 weeks: <130/80 mm Hg, N=9754 weeks: <120/80 mm Hg, N=9758 weeks: <140/90 mm Hg, N=9298 weeks: <135/80 mm Hg, N=9298 weeks: <130/80 mm Hg, N=9298 weeks: <120/80 mm Hg, N=92912 weeks: <140/90 mm Hg, N=86512 weeks: <135/80 mm Hg, N=86512 weeks: <130/80 mm Hg, N=86512 weeks: <120/80 mm Hg, N=86516 weeks: <140/90mm Hg, N=79716 weeks: <135/80mm Hg, N=79716 weeks: <130/80mm Hg, N=79716 weeks: <120/80mm Hg, N=79720 weeks: <140/90 mm Hg, N=74520 weeks: <135/80 mm Hg, N=74520 weeks: <130/80 mm Hg, N=74520 weeks: <120/80 mm Hg, N=745
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide49.123.017.37.852.429.824.811.268.140.034.317.677.851.346.228.781.355.650.128.2

Percentage of Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks

InterventionPercentage of participants (Number)
4 weeks: <90 mm Hg, N=9754weeks: <85 mm Hg, N=9754 weeks: <80 mm Hg, N=9758 weeks: <90 mm Hg, N=9298 weeks: <85 mm Hg, N=9298 weeks: <80 mm Hg, N=92912 weeks: <90 mm Hg, N=86512 weeks: <85 mm Hg, N=86512 weeks: <80 mm Hg, N=86516 weeks: <90 mm Hg, N=79716 weeks: <85 mm Hg, N=79716 weeks: <80 mm Hg, N=79720 weeks: <90 mm Hg, N=74520 weeks: <85 mm Hg, N=74520 weeks: <80 mm Hg, N=745
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide71.355.234.275.157.140.284.368.749.590.276.959.689.779.562.0

Percentage of Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks

(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks

InterventionPercentage of Participants (Number)
4 weeks: ≤ 10 mm Hg, N=9754 weeks: >10 and ≤ 15 mm Hg, N=9754 weeks: >15 and ≤ 20 mm Hg, N=9754 weeks: >20 mm Hg, N=9758 weeks: ≤ 10 mm Hg, N=9298 weeks: >10 and ≤ 15 mm Hg, N=9298 weeks: >15 and ≤ 20 mm Hg, N=9298 weeks: >20 mm Hg, N=92912 weeks: ≤ 10 mm Hg, N=86512 weeks: >10 and ≤ 15 mm Hg, N=86512 weeks: >15 and ≤ 20 mm Hg, N=86512 weeks: >20 mm Hg, N=86516 weeks: ≤ 10 mm Hg, N=79716 weeks: >10 and ≤ 15 mm Hg, N=79716 weeks: >15 and ≤ 20 mm Hg, N=79716 weeks: >20 mm Hg, N=79720 weeks: ≤ 10 mm Hg, N=74520 weeks: >10 and ≤ 15 mm Hg, N=74520 weeks: >15 and ≤ 20 mm Hg, N=74520 weeks: >20 mm Hg, N=745
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide61.321.010.57.254.720.714.110.643.824.115.816.330.422.821.525.431.419.922.626.2

Percentage of Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks

InterventionPercentage of Participants (Number)
4 weeks: <140 mm Hg, N=9754 weeks: <135 mm Hg, N=9754 weeks: <130 mm Hg, N=9754 weeks: <120 mm Hg, N=9758 weeks: <140 mm Hg, N=9298 weeks: <135 mm Hg, N=9298 weeks: <130 mm Hg, N=9298 weeks: <120 mm Hg, N=92912 weeks: <140 mm Hg, N=86512 weeks: <135 mm Hg, N=86512 weeks: <130 mm Hg, N=86512 weeks: <120 mm Hg, N=86516 weeks: <140 mm Hg, N=79716 weeks: <135 mm Hg, N=79716 weeks: <130 mm Hg, N=79716 weeks: <120 mm Hg, N=79720 weeks: <140 mm Hg, N=74520 weeks: <135 mm Hg, N=74520 weeks: <130 mm Hg, N=74520 weeks: <120 mm Hg, N=745
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide54.239.825.38.957.245.935.012.972.659.045.319.480.970.358.930.984.375.264.231.5

Percentage of Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks

(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks

InterventionPercentage of Participants (Number)
4 weeks: ≤ 15 mm Hg, N=9754 weeks: >15 and ≤ 30 mm Hg, N=9754 weeks: >30 and ≤ 45 mm Hg, N=9754 weeks: >45 mm Hg, N=9758 weeks: ≤ 15 mm Hg, N=9298 weeks: >15 and ≤ 30 mm Hg, N=9298 weeks: >30 and ≤ 45 mm Hg, N=9298 weeks: >45 mm Hg, N=92912 weeks: ≤ 15 mm Hg, N=86512 weeks: >15 and ≤ 30 mm Hg, N=86512 weeks: >30 and ≤ 45 mm Hg, N=86512 weeks: >45 mm Hg, N=86516 weeks: ≤ 15 mm Hg, N=79716 weeks: >15 and ≤ 30 mm Hg, N=79716 weeks: >30 and ≤ 45 mm Hg, N=79716 weeks: >45 mm Hg, N=79720 weeks: ≤ 15 mm Hg, N=74520 weeks: >15 and ≤ 30 mm Hg, N=74520 weeks: >30 and ≤ 45 mm Hg, N=74520 weeks: >45 mm Hg, N=745
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide51.436.610.51.545.837.714.32.330.543.122.43.923.235.932.08.920.436.234.09.4

Percentage of Patients With Metabolic Syndrome Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks

InterventionPercentage of Participants (Number)
4 weeks: <90 mm Hg, N=4544 weeks: <85 mm Hg, N=4544 weeks: <80 mm Hg, N=4548 weeks: <90 mm Hg, N=4578 weeks: <85 mm Hg, N=4578 weeks: <80 mm Hg, N=45712 weeks: <90 mm Hg, N=45712 weeks: <85 mm Hg, N=45712 weeks: <80 mm Hg, N=45716 weeks: <90 mm Hg, N=45716 weeks: <85 mm Hg, N=45716 weeks: <80 mm Hg, N=45720 weeks: <90 mm Hg, N=45720 weeks: <85 mm Hg, N=45720 weeks: <80 mm Hg, N=457
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide69.653.531.982.166.143.590.476.656.594.883.265.995.486.272.0

Percentage of Patients With Metabolic Syndrome Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks

(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks

InterventionPercentage of Participants (Number)
4 weeks: ≤ 10 mm Hg, N=4534 weeks: >10 and ≤ 15 mm Hg, N=4534 weeks: >15 and ≤ 20 mm Hg, N=4534 weeks: >20 mm Hg, N=4538 weeks: ≤ 10 mm Hg, N=4318 weeks: >10 and ≤ 15 mm Hg, N=4318 weeks: >15 and ≤ 20 mm Hg, N=4318 weeks: >20 mm Hg, N=43112 weeks: ≤ 10 mm Hg, N=40212 weeks: >10 and ≤15 mm Hg, N=40212 weeks: >15 and ≤ 20 mm Hg, N=40212 weeks: >20 mm Hg, N=40216 weeks: ≤ 10 mm Hg, N=37116 weeks: >10 and ≤ 15 mm Hg, N=37116 weeks: >15 and ≤ 20 mm Hg, N=37116 weeks: >20 mm Hg, N=37120 weeks: ≤ 10 mm Hg, N=35620 weeks: >10 and ≤ 15 mm Hg, N=35620 weeks: >15 and ≤ 20 mm Hg, N=35620 weeks: >20 mm Hg, N=356
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide62.722.38.66.456.619.715.38.444.322.117.416.232.424.021.022.633.219.422.525.0

Percentage of Patients With Metabolic Syndrome Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks

InterventionPercentage of Participants (Number)
4 weeks: <140 mm Hg, N=4544 weeks: <135 mm Hg, N=4544 weeks: <130 mm Hg, N=4544 weeks: <120 mm Hg, N=4548 weeks: <140 mm Hg, N=4578 weeks: <135 mm Hg, N=4578 weeks: <130 mm Hg, N=4578 weeks: <120 mm Hg, N=45712 weeks: <140 mm Hg, N=45712 weeks: <135 mm Hg, N=45712 weeks: <130 mm Hg, N=45712 weeks: <120 mm Hg, N=45716 weeks: <140 mm Hg, N=45716 weeks: <135 mm Hg, N=45716 weeks: <130 mm Hg, N=45716 weeks: <120 mm Hg, N=45720 weeks: <140 mm Hg, N=45720 weeks: <135 mm Hg, N=45720 weeks: <130 mm Hg, N=45720 weeks: <120 mm Hg, N=457
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide56.441.427.17.967.654.340.916.281.467.254.127.688.880.367.039.091.585.674.847.1

Percentage of Patients With Metabolic Syndrome Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks

(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks

InterventionPercentage of Participants (Number)
4 weeks: ≤ 15 mm Hg, N=4534 weeks: >15 and ≤ 30 mm Hg, N=4534 weeks: >30 and ≤ 45 mm Hg, N=4534 weeks: >45 mm Hg, N=4538 weeks: ≤ 15 mm Hg, N=4318 weeks: >15 and ≤ 30 mm Hg, N=4318 weeks: >30 and ≤ 45 mm Hg, N=4318 weeks: >45 mm Hg, N=43112 weeks: ≤ 15 mm Hg, N=40212 weeks: >15 and ≤ 30 mm Hg, N=40212 weeks: >30 and ≤ 45 mm Hg, N=40212 weeks: >45 mm Hg, N=40216 weeks: ≤ 15 mm Hg, N=37116 weeks: >15 and ≤ 30 mm Hg, N=37116 weeks: >30 and ≤ 45 mm Hg, N=37116 weeks: >45 mm Hg, N=37120 weeks: ≤ 15 mm Hg, N=35620 weeks: >15 and ≤ 30 mm Hg, N=35620 weeks: >30 and ≤ 45 mm Hg, N=35620 weeks: >45 mm Hg, N=356
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide49.538.411.50.748.035.514.42.130.443.822.63.224.037.729.19.219.736.536.07.9

Percentage of Type 2 Diabetic Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks

InterventionPercentage of Participants (Number)
4 weeks: <90 mm Hg, N=1904 weeks: <85 mm Hg, N=1904 weeks: <80 mm Hg, N=1908 weeks: <90 mm Hg, N=1908 weeks: <85 mm Hg, N=1908 weeks: <80 mm Hg, N=19012 weeks: <90 mm Hg, N=19012 weeks: <85 mm Hg, N=19012 weeks: <80 mm Hg, N=19016 weeks: <90 mm Hg, N=19016 weeks: <85 mm Hg, N=19016 weeks: <80 mm Hg, N=19020 weeks: <90 mm Hg, N=19020 weeks: <85 mm Hg, N=19020 weeks: <80 mm Hg, N=190
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide75.864.239.085.872.651.194.283.263.797.989.070.599.090.576.8

Percentage of Type 2 Diabetic Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks

(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks

InterventionPercentage of Participants (Number)
4 weeks: ≤ 10 mm Hg, N=1894 weeks: >10 and ≤ 15 mm Hg, N=1894 weeks: >15 and ≤ 20 mm Hg, N=1894 weeks: >20 mm Hg, N=1898 weeks: ≤ 10 mm Hg, N=1818 weeks: >10 and ≤ 15 mm Hg, N=1818 weeks: >15 and ≤ 20 mm Hg, N=1818 weeks: >20 mm Hg, N=18112 weeks: ≤ 10 mm Hg, N=17012 weeks: >10 and ≤15 mm Hg, N=17012 weeks: >15 and ≤ 20 mm Hg, N=17012 weeks: >20 mm Hg, N=17016 weeks: ≤ 10 mm Hg, N=15616 weeks: >10 and ≤ 15 mm Hg, N=15616 weeks: >15 and ≤ 20 mm Hg, N=15616 weeks: >20 mm Hg, N=15620 weeks: ≤ 10 mm Hg, N=15020 weeks: >10 and ≤ 15 mm Hg, N=15020 weeks: >15 and ≤ 20 mm Hg, N=15020 weeks: >20 mm Hg, N=150
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide67.716.911.63.760.820.414.93.941.232.412.913.532.726.921.818.637.318.026.018.7

Percentage of Type 2 Diabetic Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks

InterventionPercentage of Participants (Number)
4 weeks: <140 mm Hg, N=1904 weeks: <135 mm Hg, N=1904 weeks: <130 mm Hg, N=1904 weeks: <120 mm Hg, N=1908 weeks: <140 mm Hg, N=1908 weeks: <135 mm Hg, N=1908 weeks: <130 mm Hg, N=1908 weeks: <120 mm Hg, N=19012 weeks: <140 mm Hg, N=19012 weeks: <135 mm Hg, N=19012 weeks: <130 mm Hg, N=19012 weeks: <120 mm Hg, N=19016 weeks: <140 mm Hg, N=19016 weeks: <135 mm Hg, N=19016 weeks: <130 mm Hg, N=19016 weeks: <120 mm Hg, N=19020 weeks: <140 mm Hg, N=19020 weeks: <135 mm Hg, N=19020 weeks: <130 mm Hg, N=19020 weeks: <120 mm Hg, N=190
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide54.741.126.310.069.056.342.615.881.669.557.930.087.979.069.039.591.184.275.348.4

Percentage of Type 2 Diabetic Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks

(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks

InterventionPercentage of Participants (Number)
4 weeks: ≤ 15 mm Hg, N=1894 weeks: >15 and ≤ 30 mm Hg, N=1894 weeks: >30 and ≤ 45 mm Hg, N=1894 weeks: >45 mm Hg, N=1898 weeks: ≤ 15 mm Hg, N=1818 weeks: >15 and ≤ 30 mm Hg, N=1818 weeks: >30 and ≤ 45 mm Hg, N=1818 weeks: >45 mm Hg, N=18112 weeks: ≤ 15 mm Hg, N=17012 weeks: >15 and ≤ 30 mm Hg, N=17012 weeks: >30 and ≤ 45 mm Hg, N=17012 weeks: >45 mm Hg, N=17016 weeks: ≤ 15 mm Hg, N=15616 weeks: >15 and ≤ 30 mm Hg, N=15616 weeks: >30 and ≤ 45 mm Hg, N=15616 weeks: >45 mm Hg, N=15620 weeks: ≤ 15 mm Hg, N=15020 weeks: >15 and ≤ 30 mm Hg, N=15020 weeks: >30 and ≤ 45 mm Hg, N=15020 weeks: >45 mm Hg, N=150
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide56.136.07.90.054.134.311.60.035.338.222.93.528.240.426.35.126.040.026.77.3

The Percentage of Subjects Who Achieve BP Goal (<140/90 mmHg for Non-diabetics or <130/80 mmHg for Diabetics) From Baseline to 12 and 20 Weeks

(NCT00791258)
Timeframe: Baseline to 12 and 20 weeks

InterventionPercentage of participants (Number)
12 weeks20 weeks
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide71.384.8

Time-to-event Analysis of Percentage of Patients With a Cardiovascular (CV) Mortality Event, Non-fatal Myocardial Infarction (MI), or Non-fatal Stroke

CV mortality was defined as death due to sudden cardiac death, fatal MI, fatal stroke, coronary intervention, congestive heart failure (CHF), or other CV causes. (NCT00170950)
Timeframe: For each patient, baseline to time of first CV mortality event, MI (non-fatal), or stroke (non-fatal) (or last exposure if no event occurred). (Median duration of exposure was 33.4 months. [25th to 75th percentiles: 21 to 41 months.])

InterventionPercentage of Patients with an Event (Number)
Benazepril/Amlodipine5.0
Benazepril/Hydrochlorothiazide6.3

Time-to-event Analysis of Percentage of Patients With a Composite Cardiovascular (CV) Morbidity Event

Cardiovascular morbidity was defined as including any of the following events: non-fatal MI, non-fatal stroke, hospitalization for unstable angina, resuscitated sudden death, or coronary revascularization procedure (PCI or CABG). (NCT00170950)
Timeframe: For each patient, baseline to time of first CV morbidity event (or last exposure if no event occurred). (Median duration of exposure was 33.4 months. [25th to 75th percentiles: 21 to 41 months.])]

InterventionPercentage of Patients with an Event (Number)
Benazepril/Amlodipine8.6
Benazepril/Hydrochlorothiazide10.3

Time-to-event Analysis of Percentage of Patients With a Composite Cardiovascular (CV) Morbidity or Mortality Event

CV morbidity was defined as non-fatal myocardial infarction (MI), non-fatal stroke, hospitalization for unstable angina, resuscitated sudden death, or coronary revascularization procedure. CV mortality was defined as death due to MI, stroke, coronary intervention, congestive heart failure (CHF), sudden cardiac death, or other CV causes. (NCT00170950)
Timeframe: For each patient, baseline to time of first CV morbidity or mortality event (or last exposure if no event occurred). (Median duration of exposure was 33.4 months. [25th to 75th percentiles: 21 to 41 months.])

InterventionPercentage of Patients with an event (Number)
Benazepril/Amlodipine9.6
Benazepril/Hydrochlorothiazide11.8

Reviews

4 reviews available for amlodipine and Obesity

ArticleYear
Aliskiren and amlodipine in the management of essential hypertension: meta-analysis of randomized controlled trials.
    PloS one, 2013, Volume: 8, Issue:7

    Topics: Amides; Amlodipine; Antihypertensive Agents; Blood Pressure; Fumarates; Humans; Hypertension; Obesit

2013
Adiponectin effects on the kidney.
    Best practice & research. Clinical endocrinology & metabolism, 2014, Volume: 28, Issue:1

    Topics: Adiponectin; Albuminuria; Amlodipine; AMP-Activated Protein Kinases; Animals; Benzimidazoles; Benzoa

2014
Telmisartan plus amlodipine single-pill combination for the management of hypertensive patients with a metabolic risk profile (added-risk patients).
    Current medical research and opinion, 2013, Volume: 29, Issue:1

    Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzo

2013
Effects of telmisartan therapy on interleukin-6 and tumor necrosis factor-alpha levels: a meta-analysis of randomized controlled trials.
    Hypertension research : official journal of the Japanese Society of Hypertension, 2013, Volume: 36, Issue:4

    Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Blood Pressure; Calc

2013

Trials

21 trials available for amlodipine and Obesity

ArticleYear
Systemic and tissue-specific effects of aliskiren on the RAAS and carbohydrate/lipid metabolism in obese patients with hypertension.
    Journal of the American Society of Hypertension : JASH, 2017, Volume: 11, Issue:8

    Topics: Adipose Tissue; Adult; Amides; Amlodipine; Angiotensin II; Antihypertensive Agents; Blood Glucose; D

2017
The effects of angiotensin receptor neprilysin inhibition by sacubitril/valsartan on adipose tissue transcriptome and protein expression in obese hypertensive patients.
    Scientific reports, 2018, 03-02, Volume: 8, Issue:1

    Topics: Adipose Tissue; Adult; Aminobutyrates; Amlodipine; Angiotensin Receptor Antagonists; Biphenyl Compou

2018
Olmesartan/amlodipine/hydrochlorothiazide in obese participants with hypertension: a TRINITY subanalysis.
    Journal of clinical hypertension (Greenwich, Conn.), 2013, Volume: 15, Issue:8

    Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Body Mass Index; Double-Blind Meth

2013
Blood pressure control and cardiovascular outcomes in normal-weight, overweight, and obese hypertensive patients treated with three different antihypertensives in ALLHAT.
    Journal of hypertension, 2014, Volume: 32, Issue:7

    Topics: Aged; Aged, 80 and over; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agen

2014
Efficacy and tolerability of triple-combination therapy with olmesartan, amlodipine, and hydrochlorothiazide: a subgroup analysis of patients stratified by hypertension severity, age, sex, and obesity.
    Journal of clinical hypertension (Greenwich, Conn.), 2014, Volume: 16, Issue:10

    Topics: Adult; Age Factors; Aged; Amlodipine; Blood Pressure; Body Mass Index; Dose-Response Relationship, D

2014
The Effects of Valsartan and Amlodipine on the Levels of Irisin, Adropin, and Perilipin.
    Clinical laboratory, 2015, Volume: 61, Issue:12

    Topics: Adult; Amlodipine; Antihypertensive Agents; Blood Proteins; Calcium; Carrier Proteins; Female; Fibro

2015
Effect of valsartan addition to amlodipine on insulin sensitivity in overweight-obese hypertensive patients.
    Internal medicine (Tokyo, Japan), 2008, Volume: 47, Issue:21

    Topics: Adult; Aged; Amlodipine; Cross-Over Studies; Drug Therapy, Combination; Female; Humans; Hypertension

2008
Efficacy and tolerability of amlodipine plus olmesartan medoxomil in patients with difficult-to-treat hypertension.
    Journal of human hypertension, 2010, Volume: 24, Issue:11

    Topics: Age Factors; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Bla

2010
Angiotensin receptor blocker/diuretic combination preserves insulin responses in obese hypertensives.
    Journal of hypertension, 2010, Volume: 28, Issue:8

    Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Blood Glucose; Blood Pressure; Body Mass

2010
Blood pressure-lowering response to amlodipine as a determinant of the antioxidative activity of small, dense HDL3.
    American journal of cardiovascular drugs : drugs, devices, and other interventions, 2011, Oct-01, Volume: 11, Issue:5

    Topics: Aged; Amlodipine; Antihypertensive Agents; Antioxidants; Blood Pressure; Body Mass Index; Calcium Ch

2011
Office and ambulatory blood pressure-lowering effects of combination valsartan/hydrochlorothiazide vs. hydrochlorothiazide-based therapy in obese, hypertensive patients.
    Journal of clinical hypertension (Greenwich, Conn.), 2011, Volume: 13, Issue:10

    Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Co

2011
Aliskiren penetrates adipose and skeletal muscle tissue and reduces renin-angiotensin system activity in obese hypertensive patients.
    Journal of hypertension, 2012, Volume: 30, Issue:3

    Topics: Adipose Tissue; Adult; Amides; Amlodipine; Antihypertensive Agents; Calcium Channel Blockers; Extrac

2012
Efficacy of amlodipine/olmesartan medoxomil ± HCTZ in obese patients uncontrolled on antihypertensive monotherapy.
    Current medical research and opinion, 2012, Volume: 28, Issue:11

    Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Drug Therapy, Combination; Female; Humans; Hydroch

2012
Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomised controlled trial.
    Lancet (London, England), 2013, Feb-16, Volume: 381, Issue:9866

    Topics: Aged; Amlodipine; Antihypertensive Agents; Benzazepines; Body Mass Index; Body Size; Body Weight; Ca

2013
Effects of the long-acting calcium channel blockers, amlodipine, manidipine and cilnidipine on steroid hormones and insulin resistance in hypertensive obese patients.
    Internal medicine (Tokyo, Japan), 2004, Volume: 43, Issue:7

    Topics: Aged; Amlodipine; Analysis of Variance; Body Mass Index; Calcium Channel Blockers; Dehydroepiandrost

2004
Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
    Clinical therapeutics, 2005, Volume: 27, Issue:5

    Topics: Age Factors; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Cerebrovascular Disorders; D

2005
Selective imidazoline agonist moxonidine in obese hypertensive patients.
    International journal of clinical practice, 2006, Volume: 60, Issue:5

    Topics: Adult; Amlodipine; Anthropometry; Antihypertensive Agents; Female; Hemodynamics; Humans; Hypertensio

2006
Effects of amlodipine-atorvastatin combination on inflammation markers and insulin sensitivity in normocholesterolemic obese hypertensive patients.
    European journal of clinical pharmacology, 2006, Volume: 62, Issue:10

    Topics: Adult; Aged; Amlodipine; Atorvastatin; Biomarkers; Blood Glucose; Body Mass Index; Calcium Channel B

2006
Direct Renin inhibition with aliskiren in obese patients with arterial hypertension.
    Hypertension (Dallas, Tex. : 1979), 2007, Volume: 49, Issue:5

    Topics: Administration, Oral; Adult; Aged; Amides; Amlodipine; Antihypertensive Agents; Biphenyl Compounds;

2007
Direct Renin inhibition with aliskiren in obese patients with arterial hypertension.
    Hypertension (Dallas, Tex. : 1979), 2007, Volume: 49, Issue:5

    Topics: Administration, Oral; Adult; Aged; Amides; Amlodipine; Antihypertensive Agents; Biphenyl Compounds;

2007
Direct Renin inhibition with aliskiren in obese patients with arterial hypertension.
    Hypertension (Dallas, Tex. : 1979), 2007, Volume: 49, Issue:5

    Topics: Administration, Oral; Adult; Aged; Amides; Amlodipine; Antihypertensive Agents; Biphenyl Compounds;

2007
Direct Renin inhibition with aliskiren in obese patients with arterial hypertension.
    Hypertension (Dallas, Tex. : 1979), 2007, Volume: 49, Issue:5

    Topics: Administration, Oral; Adult; Aged; Amides; Amlodipine; Antihypertensive Agents; Biphenyl Compounds;

2007
Blood pressure and cardiorenal responses to antihypertensive therapy in obese women.
    Arquivos brasileiros de endocrinologia e metabologia, 2008, Volume: 52, Issue:1

    Topics: Adult; Amlodipine; Analysis of Variance; Antihypertensive Agents; Blood Pressure; Blood Pressure Mon

2008
The calcium channel blocker amlodipine raises serum dehydroepiandrosterone sulfate and androstenedione, but lowers serum cortisol, in insulin-resistant obese and hypertensive men.
    The Journal of clinical endocrinology and metabolism, 1993, Volume: 76, Issue:6

    Topics: Adult; Amlodipine; Androgens; Androstenedione; Calcium Channel Blockers; Dehydroepiandrosterone; Deh

1993

Other Studies

17 other studies available for amlodipine and Obesity

ArticleYear
Benefits of Valsartan and Amlodipine in Lipolysis through PU.1 Inhibition in Fructose-Induced Adiposity.
    Nutrients, 2022, Sep-12, Volume: 14, Issue:18

    Topics: Activating Transcription Factor 3; Adiposity; Amlodipine; Angiotensin Receptor Antagonists; Antihype

2022
Chronic blockade of angiotensin AT₁ receptors improves cardinal symptoms of metabolic syndrome in diet-induced obesity in rats.
    British journal of pharmacology, 2014, Volume: 171, Issue:3

    Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Animals; Anti-Obesity Agents; Antihypertensive

2014
Ramipril/amlodipine single pill - effectiveness, tolerance and patient satisfaction with antihypertensive therapy in relation to nutritional status.
    Pharmacological reports : PR, 2014, Volume: 66, Issue:6

    Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Drug Combinations; Humans; Hypertension; Medica

2014
Effects of antihypertensive treatment on plasma apelin, resistin, and visfatin concentrations.
    Polskie Archiwum Medycyny Wewnetrznej, 2016, Apr-29, Volume: 126, Issue:4

    Topics: Adrenergic beta-1 Receptor Antagonists; Adult; Amlodipine; Angiotensin II Type 1 Receptor Blockers;

2016
Role of diabetes and obesity in outcomes of the candesartan antihypertensive survival evaluation in Japan (CASE-J) trial.
    Hypertension research : official journal of the Japanese Society of Hypertension, 2010, Volume: 33, Issue:6

    Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles;

2010
Efficacy of amlodipine and olmesartan medoxomil in hypertensive patients with diabetes and obesity.
    Journal of clinical hypertension (Greenwich, Conn.), 2011, Volume: 13, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensiv

2011
Role of PKC and CaV1.2 in detrusor overactivity in a model of obesity associated with insulin resistance in mice.
    PloS one, 2012, Volume: 7, Issue:11

    Topics: Adiposity; Amlodipine; Animals; Body Weight; Calcium Channel Blockers; Calcium Channels, L-Type; Cal

2012
Effect of amlodipine on insulin resistance & tumor necrosis factor-alpha levels in hypertensive obese type 2 diabetic patients.
    The Indian journal of medical research, 2004, Volume: 120, Issue:5

    Topics: Adolescent; Adult; Aged; Amlodipine; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Female; Ho

2004
Adult hypertension: reducing cardiovascular morbidity and mortality.
    Prescrire international, 2005, Volume: 14, Issue:75

    Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Alcohol Drinking

2005
Angiotensin II receptor blockers downsize adipocytes in spontaneously type 2 diabetic rats with visceral fat obesity.
    American journal of hypertension, 2007, Volume: 20, Issue:4

    Topics: Adipocytes; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates;

2007
[Overweight and obesity in hypertensive Spanish patients. The CORONARIA study].
    Medicina clinica, 2007, Nov-10, Volume: 129, Issue:17

    Topics: Amlodipine; Analysis of Variance; Antihypertensive Agents; Body Mass Index; Calcium Channel Blockers

2007
Peroxynitrite is Involved in the dysfunction of vasorelaxation in SHR/NDmcr-cp rats, spontaneously hypertensive obese rats.
    Journal of cardiovascular pharmacology, 2007, Volume: 50, Issue:6

    Topics: Acetylcholine; Amlodipine; Animals; Aorta, Thoracic; Blood Glucose; Blood Pressure; Blotting, Wester

2007
ACE inhibition and AT1 receptor blockade prevent fatty liver and fibrosis in obese Zucker rats.
    Obesity (Silver Spring, Md.), 2008, Volume: 16, Issue:4

    Topics: Amlodipine; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme I

2008
[The effect on left ventricular mass of treatment with amlodipine and diet therapy in obese patients with arterial hypertension].
    Minerva cardioangiologica, 1994, Volume: 42, Issue:6

    Topics: Amlodipine; Combined Modality Therapy; Diet, Reducing; Evaluation Studies as Topic; Female; Heart Ve

1994
Lack of effect of long-term amlodipine on insulin sensitivity and plasma insulin in obese patients with essential hypertension.
    European journal of clinical pharmacology, 1993, Volume: 44, Issue:5

    Topics: Amlodipine; Blood Pressure; Female; Humans; Hypertension; Insulin; Insulin Resistance; Male; Middle

1993
Effects of amlodipine on serum levels of adrenal androgens and insulin in hypertensive men with obesity.
    Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 2001, Volume: 33, Issue:3

    Topics: Adult; Aged; Amlodipine; Calcium Channel Blockers; Dehydroepiandrosterone; Dehydroepiandrosterone Su

2001
Weight reduction and pharmacologic treatment in obese hypertensives.
    American journal of hypertension, 2001, Volume: 14, Issue:6 Pt 1

    Topics: Adult; Amlodipine; Analysis of Variance; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; C

2001